Navigation Links
SLU virologists harness adenovirus to kill breast cancer cells
Date:5/23/2014

ST. LOUIS With a $40,250 grant from the Lottie Caroline Hardy Charitable Trust Fund, researchers at Saint Louis University's Institute for Molecular Virology will study a small fragment of adenovirus as a possible future therapy for HER2 breast cancer.

Breast cancer is the most common cancer affecting women. Despite major advances, it is still the leading cause of death from cancer in women. The HER2 oncogene is implicated in 20 to 30 percent of breast cancers and has a poor prognosis. Current therapy for HER2 cancers (Herceptin and chemotherapy) is not enough to combat this deadly cancer and cannot treat a substantial number of cases.

The adenovirus is a common virus, and researcher Maurice Green, Ph.D., chair of SLU's Institute for Molecular Virology, has studied it for years. He hopes to tame the virus's abilities to kill cancer cells in order to use it as a therapy.

"It's been an ambition of mine for a long time," Green said. "Long ago, I was stationed in the Philippines, and I had nothing to do but read about medicine and that's where my interest started."

Dedicating his career to the study of virology, Green was a pioneer in using viruses to probe the functions of normal cells and to understand how cancer works on the molecular level. Green chose the adenovirus as a focus of study and he and his lab developed the first working model of the virus.

Now, Green and colleague Paul Loewenstein, assistant research professor in the department, have found that a small region of the E1A protein, an adenovirus gene, is capable of repressing HER2 cell growth.

Significantly, this function appears to be controlled by the first 80 amino acids (E1A 1-80) of the entire E1A oncogene.

This is a promising finding, because it means that researchers can focus on this small region of the adenovirus without delving into the rest of the E1A oncogene, which has other functions.

Remarkably, the expression of these 80 amino acids efficiently represses HER2 transcription and kills breast cancer cells but not normal cells.

"This is probably due to the need of the tumor cells for continued overexpression of the HER2 oncogene for growth and survival. This phenomenon has been termed 'oncogene addiction,'" Green said.

One of the exciting possibilities of E1A 1-80 is that it seems to be effective against cancer cells over-expressing other HER family members, besides HER2. Potentially, E1A 1-80 could be used against tumors of the prostate, ovaries, colon, and head and neck, as well as breast cancer.

With this grant, Green and Loewenstein want to develop a strong E1A 1-80 HER2 repressor that may someday be added to Herceptin therapy. Their work will include animal model studies to further demonstrate the potential of E1A 1-80 as a therapy.

And, Green sees particular promise in this gene therapy because it seems to kill not only tumor cells, but targets their origins, as well.


'/>"/>

Contact: Carrie Bebermeyer
bebermcl@slu.edu
314-977-8015
Saint Louis University
Source:Eurekalert  

Related medicine news :

1. Virus detector harnesses ring of light in whispering gallery mode
2. Revolutionary techniques could help harness patients own immune cells to fight disease
3. MU scientists build harness for powerful radiation cancer therapy
4. Solatube International Celebrates Earth Day 2013 by Harnessing the Sun’s Rays with Daylighting
5. New Survey Findings: Application Intelligence and Connected Devices - How do you Harness the Value?
6. Total Knee Replacement Surgeons at Bethesda Health Offer New Technology that Harnesses Intelligent Orthopaedic Surgery Using The VERASENSE Knee System
7. Secrets to Success
8. “Harness The Hidden Laws Of The Universe” Helps People Create the Life of Their Dreams – V kool
9. Penn Medicine researchers harness the immune system to fight pancreatic cancer
10. UNC researchers harness suns energy during day for use at night
11. Recombinant adenovirus-mediated 3β-hydroxysteroid-Δ24 reductase inhibits neural apoptosis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
SLU virologists harness adenovirus to kill breast cancer cells
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening to conquer ... in advanced audiology and hearing aid technology, has today ... world,s first internet connected hearing aid that opens up ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... , TwinLink™ - the first dual communication ...
(Date:6/23/2016)... Research and Markets has announced ... Analysis (United States, China, Japan, Brazil, United Kingdom, Germany, ... offering. Surgical Procedure ... planners, provides surgical procedure volume data in a geographic ... in-depth analysis of growth drivers and inhibitors, including world ...
(Date:6/23/2016)...  The National Pharmaceutical Council (NPC) today announced ... research organization as its newest member.  ... president and chief scientific officer, Mallinckrodt Pharmaceuticals, will ... Board of Directors. ... us in support of our efforts to conduct ...
Breaking Medicine Technology: